Phage therapy program
Intralytix
| Status | Official referral/inquiry route |
|---|---|
| Type | Supplier |
| Location | Columbia, Maryland; United States |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Only a qualified licensed treating physician may request expanded access at ExpandedAccess@intralytix.com. Case-by-case review requires serious/life-threatening bacterial disease, exhausted alternatives, trial ineligibility, consent, regulatory approvals, monitoring and adequate product supply. |
|---|---|
| Areas of work | Supplier expanded access plus EcoActive, ShigActive and VRELysin clinical development; fixed indications and product availability limit access. |
| International access | Policy requires compliance with regulations in the intended-use country; no blanket international acceptance or export commitment is verified. |
What to confirm
- Published policy is not a guarantee of supply. Company trial descriptions may lag registry statuses.
Related studies(3)
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
Conflicting status
Recorded program–study link. Website
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
Active, not recruiting
Recorded program–study link. Website
Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects
Suspended
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- Intralytix Expanded Access Policy
- Intralytix Clinical Trials
- NCT03808103 — ClinicalTrials.gov
- NCT05182749 — ClinicalTrials.gov
- NCT05715619 — ClinicalTrials.gov
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | intralytix |
|---|